From the official registers: KBO 5 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
Magis Pharma Group is a financial institution. The bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €530,028 and a net result of -€399,056. Equity has been shrinking by about 54% per year since 2021. Its solvency ranks better than 7% of 3,028 sector peers (NACE 64, financial year 2025). The company has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals.
Directors
Board 4
Day-to-day management 2
Permanent representatives 2
Statutory auditor 1
Mandate history
- Board
- Day-to-day management
- Statutory auditor
- began earlier
| Name | Functions and periods |
|---|---|
| De Vogel Paulus |
|
| DB Consortium |
|
| GREEN MONKEY |
|
| Constantijn van Rietschoten |
|
| NV Callens Vandelanotte |
|
| Jeroen van der Hamsvoort |
|
| TJ Management |
|
| BD Strategy |
|
| Jacob Vermeule |
|
The board according to the articles of association
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- “Het mandaat van de bovenvermelde bestuurder wordt onbezoldigd uitgeoefend. Overeenkomstig artikel 19 van de statuten van de Vennootschap…”
Articles of association, deed of 21-10-2026
Owners and capital
Capital transactions
- CEBAN INTERMEDIATE HOLDING B.V (BE 0785.812.044) in cash
- JACOBS Toon Anne Paul in cash
- 28-07-2022 Capital increase of €2,000,000.81 · 2,000,000 new shares
Other provisions of the articles of association
- Other provisionsThese rules from the articles cover subjects other than the board, the shares, the purpose and the meetings.
- “Mogelijkheid voor een gedelegeerd bestuurder of persoon belast met het dagelijks bestuur (binnen de grenzen van het dagelijks bestuur) c.q…”
Articles of association, deed of 08-06-2026 (in Dutch)